362 related articles for article (PubMed ID: 34456921)
21. Pseudorabies Virus Infection Causes Downregulation of Ligands for the Activating NK Cell Receptor NKG2D.
Denaeghel S; De Pelsmaeker S; Van Waesberghe C; Favoreel HW
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572245
[TBL] [Abstract][Full Text] [Related]
22. Regulation of NKG2D Expression and Signaling by Endocytosis.
Molfetta R; Quatrini L; Zitti B; Capuano C; Galandrini R; Santoni A; Paolini R
Trends Immunol; 2016 Nov; 37(11):790-802. PubMed ID: 27667711
[TBL] [Abstract][Full Text] [Related]
23. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
24. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
25. Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Okita R; Wolf D; Yasuda K; Maeda A; Yukawa T; Saisho S; Shimizu K; Yamaguchi Y; Oka M; Nakayama E; Lundqvist A; Kiessling R; Seliger B; Nakata M
PLoS One; 2015; 10(10):e0139809. PubMed ID: 26439264
[TBL] [Abstract][Full Text] [Related]
26. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
27. Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia.
Wu Z; Zhang H; Wu M; Peng G; He Y; Wan N; Zeng Y
Biomed Pharmacother; 2021 May; 137():111299. PubMed ID: 33508619
[TBL] [Abstract][Full Text] [Related]
28. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
29. Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV.
El Sobky SA; El-Ekiaby NM; Mekky RY; Elemam NM; Mohey Eldin MA; El-Sayed M; Esmat G; Abdelaziz AI
Immunol Lett; 2016 Jan; 169():52-60. PubMed ID: 26518141
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous knockdown of multiple ligands of innate receptor NKG2D prevents natural killer cell-mediated fulminant hepatitis in mice.
Huang M; Sun R; Wei H; Tian Z
Hepatology; 2013 Jan; 57(1):277-88. PubMed ID: 22806577
[TBL] [Abstract][Full Text] [Related]
31. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Schmiedel D; Mandelboim O
Front Immunol; 2018; 9():2040. PubMed ID: 30254634
[TBL] [Abstract][Full Text] [Related]
32. NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications.
Siemaszko J; Marzec-Przyszlak A; Bogunia-Kubik K
Cells; 2021 Jun; 10(6):. PubMed ID: 34200375
[TBL] [Abstract][Full Text] [Related]
33. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
34. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
Jensen H; Andresen L; Nielsen J; Christensen JP; Skov S
PLoS One; 2011; 6(8):e23023. PubMed ID: 21857986
[TBL] [Abstract][Full Text] [Related]
35. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
[TBL] [Abstract][Full Text] [Related]
36. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
37. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
38. Viral Evasion of Natural Killer Cell Activation.
Ma Y; Li X; Kuang E
Viruses; 2016 Apr; 8(4):95. PubMed ID: 27077876
[TBL] [Abstract][Full Text] [Related]
39. Differential Effects of Histone Deacetylases on the Expression of NKG2D Ligands and NK Cell-Mediated Anticancer Immunity in Lung Cancer Cells.
Cho H; Son WC; Lee YS; Youn EJ; Kang CD; Park YS; Bae J
Molecules; 2021 Jun; 26(13):. PubMed ID: 34203519
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.
Chen S; Yu X; Guo D
Viruses; 2018 Jan; 10(1):. PubMed ID: 29337866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
